Low molecular weight heparin in acute coronary syndrome: Evidence for superior or equivalent efficacy compared with unfractionated heparin?

Journal of the American College of Cardiology

Volumn 35, Issue 7, 2000, Pages 1699-1712

  Kaul, Sanjay ^a   Shah, Prediman K ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG EFFICACY; DRUG HALF LIFE; DRUG SCREENING; DRUG UTILIZATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; MEDICAL INSTRUMENTATION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; ST SEGMENT ELEVATION; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

EID: 0034042313     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00648-3     Document Type: Review

References (35)

1. Weitz J.I. Low-molecular-weight heparins. N Engl J Med. 337:1997;688-698.
2. Frydman A.M. Low-molecular weight heparins an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans . Haemostasis. 26:(Suppl 2):1996;2-9.
3. Xiao Z., Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 97:1998;251-256.
4. Warkentin T.E., Levine M.N., Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 332:1995;1330-1335.
5. Hoppensteadt D.A., Jeske W., Fareed J., Bermes E.W. Jr. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagul Fibrinolysis. 6:1995;S57-S64.
6. Toschi V., Gallo R., Lettino M., et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 95:1997;594-599.
7. Montalescot G., Philippe F., Ankri A., et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease beneficial effects of enoxaparin . Circulation. 98:1998;294-299.
8. Antman E.M., Handin R. Low-molecular-weight heparins an intriguing new twist with profound implications . Circulation. 98:1998;287-289.
9. Fareed J., Jeskie W., Hoppensteadt D., Clarizo R., Walenga J.M. Are the available low-molecular-weight heparin preparations the same? Sem Thromb Hemost. 22:1996;77-91.
10. Collignon F., Frydman A., Caplain H., et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost. 73:1995;630-640.
11. Kuijer P.M.M., Prins M.H., Buller H.R. Low-molecular-weight heparins treatment of venous thromboembolism . Sasahara A.A., Loscalzo J. Advances in Therapeutic Agents in Thrombosis and Thrombolysis. 1997;129-147 Dekker, New York.
12. Hirsh J. Low-molecular-weight heparin a review of the results of recent studies of the treatment of venous thromboembolism and unstable angina . Circulation. 98:1998;1575-1582.
13. Gurfinkel E.P., Manos E.J., Mejail R.I., et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol. 26:1995;313-318.
14. Verheugt F.W.A. Hotline sessions at the 20th European Congress of Cardiology. Eur Heart J. 20:1999;7-10.
15. Low-molecular-weight heparin during instability in coronary artery disease. Lancet. 347:1996;561-568.
16. Klein W., Buchwald A., Hillis S.E., et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for six weeks in the management of unstable coronary artery disease Fragmin in Unstable Coronary Artery Disease Study (FRIC) . Circulation. 96:1997;61-68.
17. Long-term low-molecular-mass heparin in unstable coronary-artery disease FRISC II prospective randomized multicenter study . Lancet. 354:1999;701-707.
18. Invasive compared with non-invasive treatment in unstable coronary-artery disease FRISC II prospective randomised multicentre study . Lancet. 354:1999;708-715.
19. Cohen M., Demers C., Gurfinkel E.P., et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 337:1997;447-452.
20. Dose-ranging trial of enoxaparin for unstable angina results of TIMI 11A . J Am Coll Cardiol. 29:1997;1474-1482.
21. Antman E.M., McCabe C.H., Gurfinkel E.P., et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial . Circulation. 100:1999;1593-1601.
22. Goodman S., Bigonzi F., Radley D.R., Le Louer V., Gosset F., Cohen M. One-year follow-up of the ESSENCE trial (abstr). Eur Heart J. 19:(Suppl):1998;#P477.
23. Mark D.B., Cowper P.A., Berkowitz S.D., et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients results from the ESSENCE randomized trial . Circulation. 97:1998;1702-1707.
24. Raschke R.A., Reilly B.M., Guidry J.R., Fontana J.R., Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram a randomized controlled trial . Ann Intern Med. 119:1993;874-881.
25. Antman E.M., Cohen M., Radley D.R., et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q wave myocardial infarction TIMI-11B-ESSENCE meta-analysis . Circulation. 100:1999;1602-1608.
26. Eikelboom JW, Anand SS, Malmberg KA, Weitz J, Ginsberg JS, Yusuf S. Unfractionated heparin (UFH) and low-molecular weight heparin (LMWH) in unstable angina and non-Q wave myocardial infarction: a meta-analysis (abstr). Circulation 1999;100:1-621.
27. Califf R.M., Abdelmeguid A.E., Kuntz R.E., et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol. 31:1998;241-251.
28. Baim D.S., Cutlip D.E., Sharma S.K., et al. Final results of the Balloon versus Optimal Atherectomy trial. Circulation. 97:1998;322-331.
29. Kini A., Marmur J.D., Kini S. Creatine kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-to-medium level elevation has a benign clinical course implications for early discharge after coronary intervention . J Am Coll Cardiol. 34:1999;3:663-3:671.
30. Lovenox [package insert]. Rhone-Poulenc Rorer Pharmaceuticals Inc., Collegeville, Pennsylvania.
31. Deutsch E., Cohen M., Radley D.R., Tarazona N., Fromell G.J. Safety and efficacy of percutaneous procedures in patients receiving subcutaneous enoxaparin for unstable angina results of the ESSENCE trial (Abstr) . Circulation. 98:1998;1-563.
32. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 335:1996;775-782.
33. Data on file, Rhone-Poulenc Rorer Pharmaceuticals Inc., Collegeville, Pennsylvania, 1999.
34. Zidar J.P. Low molecular weight heparins in coronary stenting (the ENTICES trial). Am J Cardiol. 82:(Suppl):1998;29L-31L.
35. Chamuleau S.A., de Winter R.J., Levi M., et al. Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction the FATIMA study. Fraxiparin Anticoagulant Therapy in Myocardial Infarction Study Amsterdam (FATIMA) study group . Heart. 80:1998;35-39.